Federico Alberici

5.7k total citations
86 papers, 2.0k citations indexed

About

Federico Alberici is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Nephrology. According to data from OpenAlex, Federico Alberici has authored 86 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 29 papers in Rheumatology and 19 papers in Nephrology. Recurrent topics in Federico Alberici's work include Vasculitis and related conditions (29 papers), Renal Diseases and Glomerulopathies (14 papers) and Otitis Media and Relapsing Polychondritis (10 papers). Federico Alberici is often cited by papers focused on Vasculitis and related conditions (29 papers), Renal Diseases and Glomerulopathies (14 papers) and Otitis Media and Relapsing Polychondritis (10 papers). Federico Alberici collaborates with scholars based in Italy, United Kingdom and United States. Federico Alberici's co-authors include David Jayne, Augusto Vaglio, Rona Smith, Rachel Jones, Darren M. Roberts, Stella Burns, Carlo Buzio, Francesco Scolari, Alessandra Palmisano and Elisa Delbarba and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Federico Alberici

75 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Federico Alberici Italy 22 783 737 384 345 341 86 2.0k
Cloé Comarmond France 26 1.1k 1.4× 853 1.2× 338 0.9× 446 1.3× 234 0.7× 59 2.5k
A. Néel France 25 706 0.9× 455 0.6× 112 0.3× 565 1.6× 240 0.7× 100 2.0k
Syuji Takei Japan 26 473 0.6× 1.2k 1.6× 180 0.5× 750 2.2× 456 1.3× 108 2.7k
Vicente Rodríguez‐Valverde Spain 26 1.2k 1.5× 2.0k 2.8× 327 0.9× 660 1.9× 421 1.2× 67 3.2k
Shigeko Inokuma Japan 24 564 0.7× 1.3k 1.7× 71 0.2× 421 1.2× 351 1.0× 78 2.4k
Karim Sacré France 26 531 0.7× 881 1.2× 95 0.2× 620 1.8× 237 0.7× 116 2.1k
Jean‐Emmanuel Kahn France 22 1.0k 1.3× 1.5k 2.0× 147 0.4× 751 2.2× 1.0k 3.0× 100 2.6k
Sevil Kamalı Türkiye 21 453 0.6× 790 1.1× 151 0.4× 415 1.2× 147 0.4× 72 1.7k
Gülen Hatemi Türkiye 31 1.7k 2.2× 1.8k 2.5× 105 0.3× 433 1.3× 284 0.8× 189 4.1k
Nicolas Limal France 20 269 0.3× 376 0.5× 164 0.4× 283 0.8× 181 0.5× 47 1.5k

Countries citing papers authored by Federico Alberici

Since Specialization
Citations

This map shows the geographic impact of Federico Alberici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Alberici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Alberici more than expected).

Fields of papers citing papers by Federico Alberici

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Alberici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Alberici. The network helps show where Federico Alberici may publish in the future.

Co-authorship network of co-authors of Federico Alberici

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Alberici. A scholar is included among the top collaborators of Federico Alberici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Alberici. Federico Alberici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peyronel, Francesco, Alessandra Palmisano, Federica Maritati, et al.. (2025). Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. Journal of Autoimmunity. 157. 103487–103487.
2.
Ramirez, Giuseppe A., Tommaso Schioppo, Lorenza Maria Argolini, et al.. (2025). Long Term Outcomes of Anti-COVID-19 Vaccines in Patients with Systemic Lupus Erythematosus: A Multicentre Study. Vaccines. 13(7). 735–735.
3.
4.
Scalamogna, Antonio, et al.. (2025). Incremental peritoneal dialysis: less is more—for the patient and the planet. Frontiers in Medicine. 12. 1676396–1676396.
5.
Alberici, Federico, et al.. (2024). Treatment goals in ANCA-associated vasculitis: defining success in a new era. Frontiers in Immunology. 15. 1409129–1409129. 3 indexed citations
6.
Baragetti, Ivano, Lucia Del Vecchio, Francesca Ferrario, et al.. (2024). The safety of corticosteroid therapy in IGA nephropathy: analysis of a real-life Italian cohort. Journal of Nephrology. 38(1). 225–234. 3 indexed citations
7.
Dordoni, Chiara, Letizia Zeni, Cinzia Mazza, et al.. (2024). Monoallelic pathogenic IFT140 variants are a common cause of autosomal dominant polycystic kidney disease–spectrum phenotype. Clinical Kidney Journal. 17(2). sfae026–sfae026. 5 indexed citations
8.
Alberici, Federico, Federica Mescia, & Francesco Scolari. (2023). The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab. Clinical Kidney Journal. 16(9). 1426–1431. 3 indexed citations
9.
Bertoni, Anna, et al.. (2023). #6292 PSYCHOLOGICAL CHALLENGES OF THE PATIENT STARTING PERITONEAL DIALYSIS. Nephrology Dialysis Transplantation. 38(Supplement_1). 1 indexed citations
10.
Bolognesi, Maddalena M., Albino Eccher, Federico Alberici, et al.. (2023). Congo Red Staining in Digital Pathology: The Streamlined Pipeline for Amyloid Detection Through Congo Red Fluorescence Digital Analysis. Laboratory Investigation. 103(11). 100243–100243. 8 indexed citations
11.
Mescia, Federica, Chiara Salviani, M. Tonoli, et al.. (2023). Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function. Nephrology Dialysis Transplantation. 39(4). 683–693. 7 indexed citations
12.
Gerosa, Maria, Tommaso Schioppo, Lorenza Maria Argolini, et al.. (2022). The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. Vaccines. 10(5). 663–663. 15 indexed citations
13.
Delbarba, Elisa, Domenico Santoro, Loreto Gesualdo, et al.. (2020). Rituximab vs. Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Trial. Journal of the American Society of Nephrology. 31(10S). B9–B9. 1 indexed citations
14.
Moroni, Gabriella, Mariele Gatto, Silvana Quaglini, et al.. (2020). Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Annals of the Rheumatic Diseases. 79(8). 1077–1083. 60 indexed citations
15.
Francesco, Maria Antonia De, Federico Alberici, Nicola Bossini, et al.. (2020). Pneumocystis jirevocii and SARS-CoV-2 Co-Infection: A Common Feature in Transplant Recipients?. Vaccines. 8(3). 544–544. 21 indexed citations
16.
Kronbichler, Andreas, Julia Kerschbaum, Seerapani Gopaluni, et al.. (2018). Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases. 77(10). 1440–1447. 89 indexed citations
17.
Passalacqua, Rodolfo, Caterina Caminiti, Sebastiano Buti, et al.. (2014). Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC). Journal of Immunotherapy. 37(9). 440–447. 59 indexed citations
18.
Roberts, Darren M., Rachel Jones, Richard Smith, et al.. (2014). Rituximab-Associated Hypogammaglobulinaemia: Incidence, Outcomes and Effect of Dose in Patients with Multi-System Autoimmune Disease. Nephrology. 19. 64–64. 1 indexed citations
19.
Vaglio, Augusto, Johanna Strehl, B. Manger, et al.. (2011). IgG4 immune response in Churg–Strauss syndrome. Annals of the Rheumatic Diseases. 71(3). 390–393. 123 indexed citations
20.
Suppiah, Ravi, Chetan Mukhtyar, Federico Alberici, et al.. (2010). MEASUREMENT OF DAMAGE IN SYSTEMIC VASCULITIS: A COMPARISON OF THE VASCULITIS DAMAGE INDEX (VDI) WITH THE COMBINED DAMAGE ASSESSMENT INDEX (CDA). Oxford University Research Archive (ORA) (University of Oxford). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cloé Comarmond Breakdown of academic impact, for papers by A. Néel Breakdown of academic impact, for papers by Syuji Takei Breakdown of academic impact, for papers by Vicente Rodríguez‐Valverde Breakdown of academic impact, for papers by Shigeko Inokuma Breakdown of academic impact, for papers by Karim Sacré Breakdown of academic impact, for papers by Jean‐Emmanuel Kahn Breakdown of academic impact, for papers by Sevil Kamalı Breakdown of academic impact, for papers by Gülen Hatemi Breakdown of academic impact, for papers by Nicolas Limal
Rankless by CCL
2026